European-Latin American TB research Collaboration Network (EUSAT-RCS)
Aim: to strenghten TB Research Collaboration Network (EUSAT-RCS), offer capacity building and build up a Latin American TB clinical hub.
EUSAT-RCS sets out to train a new generation of interdisciplinary scientists through performing research with three specific objectives:
A. to investigate little explored aspects of TB drug treatment as pharmacokinetics and pharmacogenetics
B. to validate a portable, battery loaded Electronic Nose (eNose) device; a novel and very promising 'point of
care'diagnostic method for TB
C. evaluate an eNose device as a biomarker of response to treatment.
Enhancing the potential and future career prospects of the staff members
Contribution to realising the potential of individuals
Bringing together a diverse group of organisations from 2 different continents in itself already provides the involved individuals with valuable knowledge and insights yet working towards a similar goal via research activities and joint training will greatly enhance this. On an individual level, the ESRs and ERs will have the opportunity to learn from each other the state-of-the-art methodologies and approaches in current TB clinical research, under guidance of experienced leaders. Each research WP will allow these researchers to develop their talents and to align their complementary expertise to achieve scientific objectives, whilst making new friends along the way.
For ESRs the opportunity to travel to other countries, work on highly relevant TB questions and have access to quality training will make them highly interesting future employees for TB research groups around the world. Having the backing of a strong, well developed network of TB researchers will improve their opportunities to acquire funding and set out the course for their own career in TB clinical research.
Quality and efficiency of the implementation
Please note that the principles of the European Charter for Researchers and Code of Conduct for the Recruitment of Researchers promoting open recruitment and attractive working conditions are recommended to be endorsed and applied by all the funded participating organisations in the MSCA. In all cases, the Beneficiaries must take all specific steps and measures to implement the principles set out in the European Charter for Researchers and the Code of Conduct for their Recruitment.
Geert Grooteplein Zuid 10
6525 GA Nijmegen
RadboudUMC-Center for infectious diseases: our scientific research combines basic science with pharmacology, microbiology, radiology, infectiology, and lung diseases. The knowledge gained contributes to expertise regarding the diagnosis and treatment of patients with tuberculosis and NTM infections. We focus on drug treatment, mycobacterial diagnosis, and inflammation and susceptibility.
The scientific research into TBC and NTM falls under the research theme Infectious Diseases and Global Health and takes place in the research institutes Radboud Institute for Health Sciences and Radboud Institute for Molecular Life Sciences.
Dr. Cecile Magis
Instituto de Saúde Pública (ISPUP)
At ISPUP we consider essential to establish and promote a lively and active relationship with the media, in order to accomplish our mission of disseminating science and health education among the population.
It is a priority for us to foster the connection between science and society, ensuring that our scientists are playing an important role of being sources of information in the media routine process.
Universidade do Porto
Praca Gomes Teixeira
4099 002 Porto
Dr. Cecile Magis-Escurra
Prof. Henrique Barros
Hospital Universitario Vall d'Hebron
Passeig Vall d'Hebron 119-129
At Vall d’Hebron Barcelona Hospital Campus we are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare. We have three research institutes dedicated to transferring problems from the consulting room to the laboratory, and the solutions found there directly to patients.
We work to understand diseases, to know how they function and to create better treatments that can be applied to patients in the real world. The huge potential of our Hospital Campus in the field of research is reflected in the excellence of the work done in parallel between research centres and hospitals. We have an opportunity to see conditions first-hand and to work to provide solutions.
Dr. Adrian Sanchez
Dr. Sarita Aguirre Garcia
Dr. Felipe Gonzalez
Universitair Medisch Centrum Groningen
The University Medical Center Groningen (UMCG) was established in 2005 as a joint activity of the University of Groningen and the Academic Hospital Groningen (AZG). At present, the UMCG is one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands.
Research at the UMCG is characterized by a combination of fundamental and patient oriented clinical research. The interaction between these two stimulates the development of new clinical and research opportunities.
Problems that occur in the clinical practice act as a catalyst which sets new fundamental research in motion, whereas fundamental research can come up with new clinical possibilities.
Dr. Jan-Willem Alffenaar
Dr. Felipe Gonzalez
The current organization of The eNose Company was founded in 2013. We focus on disease screening using exhaled-breath analysis. For this purpose, a dedicated point-of-care electronic nose was developed (Aeonose). After finishing a number of pilot studies in oncology, infectious-, and neurological diseases, The eNose Company now focuses on colon cancer, lung cancer, tuberculosis, and fasting. In 2014, the Aeonose received a CE-mark, and in 2015 the company was ISO 13485 certified.
The eNose Company develops diagnostic tools for screening of diseases through exhaled breath in order to ease patients’ lives, provide physicians with additional diagnostic tools, and lower the burden of the healthcare community.
Dr. Jan-Willem Gerritsen
TASK Applied Science
Cape Town, 7500
TASK Applied Science (TASK) is a clinical research centre in Cape Town, South Africa with a focus on performing clinical trials in tuberculosis (TB). TASK provides assistance to efficiently conduct studies for diagnosis, treatment or prevention of tuberculosis, as well as for other prevalent diseases such as asthma, osteoarthritis and vaccine studies like respiratory syncytial virus (RSV), where new and improved treatments are urgently needed.
The company was founded in 2005 by Prof. Andreas Diacon to accelerate the development and evaluation of novel anti-tuberculosis drugs. TASK mainly collaborates with international NGOs, government funded consortia, academic centers and pharmaceutical companies on various drug development projects.